Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
FDA Grants Approval to New Dosing Regimen for Asparaginase Erwinia Chrysanthemi in ALL/LBLNovember 18th 2022
Patients with acute lymphocytic leukemia or lymphoblastic lymphoma can now receive asparaginase erwinia chrysanthemi at 25 mg/m2 on Monday and Wednesday followed by 50 mg/m2 on Friday, or 25 mg/m2 every 48 hours.
Ponatinib/Chemotherapy Improves MRD-Negative CRs Vs Imatinib in Ph+ ALLNovember 18th 2022
Among patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, ponatinib plus chemotherapy yielded higher rates of minimal residual disease–negative complete remission compared with imatinib.
Zolbetuximab Reaches PFS End Point in CLDN18.2+ HER2– Advanced/Metastatic Gastric/GEJ AdenocarcinomaNovember 17th 2022
Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Companion Diagnostic FOLR1-2.1 for Identification of Epithelial Ovarian Cancer Eligible for Mirvetuximab Soravtansine-gynxNovember 16th 2022
The VENTANA FOLR1 RxDx Assay has received approval from the FDA for identifying epithelial ovarian cancer in patients who may be eligible for treatment with mirvetuximab soravtansine-gynx.
Fruquintinib/Paclitaxel Meets PFS End Point in Second-Line Gastric Cancer TrialNovember 16th 2022
Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.
Letrozole/Abemaciclib Demonstrate Promising, Long-Lasting Activity in Recurrent ER+ Endocrine CancerNovember 14th 2022
In patients with estrogen receptor–positive recurrent endometrial cancer, letrozole and abemaciclib combination therapy produced an objective response rate of 30% and a median progression-free survival of 9.1 months.
TAC01-HER2 Cell Therapy Demonstrates Promising Clinical Activity in HER2+ Solid TumorsNovember 14th 2022
Interim data from the phase 1/2 TACTIC-2 trial indicated that treatment with TAC01-HER2 cell therapy produced a 67% disease control rate among a cohort of patients with HER2-positive solid tumors.
PSMA-PET SUVmean Predictive of Favorable Response to 177Lu-PSMA-617 Than Cabazitaxel in mCRPCNovember 10th 2022
According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
PTCV Plus pIL-12 and Pembrolizumab Demonstrates Promising Responses in Unresectable/Metastatic HCCNovember 8th 2022
A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.
89Zr-DFO-Girentuximab PET Agent Meets Specificity and Sensitivity End Points in Clear Cell RCCNovember 8th 2022
The investigational imaging agent 89ZR-DFO-girentuximab met all primary and secondary end points, exceeding pre-determined sensitivity and specificity targets in clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.
Brentuximab Vedotin Plus Chemotherapy Improves EFS Vs Chemotherapy Alone in Advanced Hodgkin LymphomaNovember 8th 2022
Findings from a randomized phase 3 trial indicated that brentuximab vedotin plus chemotherapy yielded a higher event-free survival rate and lowered the risk of death compared with chemotherapy alone among patients with advanced-stage Hodgkin Lymphoma.
Real-World Study Highlights Poor OS in Relapsed/Refractory MCL Following BTK Inhibitor FailureNovember 7th 2022
Real-world results from the retrospective SCHOLAR-2 study provided a benchmark for survival in patients with relapsed or recurrent refractory mantle cell lymphoma who received salvage therapy following failure of initial Bruton tyrosine kinase inhibitor therapy.
Iomab-B With Subsequent Bone Marrow Transplant Meets dCR End Point in Relapsed/Refractory AMLNovember 1st 2022
A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission compared with conventional care in elderly patients with relapsed or refractory acute myeloid leukemia.
Luspatercept-aamt Yields Improved RBC-TI and Hemoglobin Increase Vs Epoetin Alfa in MDSNovember 1st 2022
Among adult patients with low- or intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions, luspatercept-aamt improved red blood cell transfusion independence with concurrent hemoglobin increase compared with epoetin alfa.
Darolutamide Plus ADT and Docetaxel Improves Quality of Life Vs Placebo in mHSPCOctober 31st 2022
Quality of life data from the phase 3 ARASENS study highlighted how early treatment intensification with darolutamide plus standard androgen deprivation therapy and docetaxel improved patient-relevant end points compared with placebo in the management of metastatic hormone-sensitive prostate cancer.
Camizestrant Meets PFS End Point Vs Fulvestrant in ER+ Advanced/Metastatic Breast CancerOctober 30th 2022
Oral selective estrogen receptor degrader camizestrant elicited a statistically significant and clinically meaningful progression-free survival benefit compared with fulvestrant among patients with estrogen receptor–positive locally advanced or metastatic breast cancer.
Concomitant H-WBI Yields Non-Inferior IBR, Shorter Treatment Time Vs Sequential WBI in High-Risk Early Breast CancerOctober 30th 2022
Supplemental radiation doses delivered concomitantly with hypofractionated whole breast irradiation in 15 fractions demonstrated non-inferior ipsilateral breast recurrence and similar toxicity compared with sequential boosts following whole breast irradiation in high-risk early-stage breast cancer.
ER Antagonist OP-1250 Demonstrates Continued Anti-Tumor Activity in Advanced ER+ HER2– Breast CancerOctober 29th 2022
Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions.
Rogaratinib Demonstrates Comparable Efficacy and Safety Vs Chemotherapy in FGFR+ Advanced Urothelial CarcinomaOctober 27th 2022
Rogaratinib showed similar efficacy and manageable safety compared with chemotherapy in the management of FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma.
Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCCOctober 25th 2022
Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.
Cabazitaxel at Lowered Dose, Increased Frequency Reduces Neutropenic Complications in Older Patients With mCRPCOctober 25th 2022
Based on findings from the phase 3 CABASTY trial, a fixed 16 mg/m2 dose of cabazitaxel every 2 weeks vs 25 mg/m2 every 3 weeks reduced neutropenic complications in elderly patients with mCRPC.
Conventional Radiotherapy and 5 Fraction SBRT Produce Comparable Toxicity in Prostate CancerOctober 24th 2022
According to findings from the phase 3 PACE-B trial, genitourinary and gastrointestinal toxicities were similar among patients with prostate cancer receiving conventionally fractioned or moderately hypofractionated radiotherapy and stereotactic body radiotherapy.
European Commission Grants Approval to Second-Line Axicabtagene Ciloleucel for R/R DLBCL/HGBLOctober 22nd 2022
The European Commission based its approval of axicabtagene ciloleucel as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma on the efficacy findings of the phase 3 ZUMA-7 trial.
Pembrolizumab Plus Chemotherapy Demonstrates Continued Benefit in Recurrent/Metastatic HNSCCOctober 21st 2022
Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.